Cell and Gene Therapy Manufacturing Market Research and Forecast 2023 to 2033
The global Cell and Gene Therapy Manufacturing Market is worth US$ 19.3 Billion as of now and expected to reach US$ 240 Billion by the year 2033 at a staggering CAGR of 29% between 2023 and 2033.
The changing landscape
of treating chronic ailments through advanced therapies is the key factor
driving the cell and gene therapy manufacturing market. The key players have
expanded their manufacturing capabilities regarding vector production and have
also undertaken several strategic initiatives for producing investigational
therapies. Along these lines, BioCardia Inc., in April 2022, did declare that
the US FDA approved its IND applications for Covid-19 stem cell therapy to
treat patients recovering from Acute Respiratory Distress owing to SARS-CoV-2.
As of May 2022, ~300
cell and gene therapies are under clinical trial and expected to grow on a
significant count in the years to come.
Research states that
nearly 35% of process gets outsourced with conventional biologics and over 65%
of the production process for gene and cell therapies gets outsourced. This
could be reasoned with the fact that almost 67% of innovations regarding the
space is gone through by small firms lacking expertise, capacity, and resources
to commercialize the products.
Future Market Insights
has walked through these facts with future perspectives in its latest market
study entitled ‘Cell and Gene Therapy Manufacturing market’. The line of
expertise in the form of analyst and consultants is there to execute through
bottom-up approach.
“With advanced
therapies transforming paradigm of treatment in several rare and
life-threatening diseases along with reshaping biopharmaceutical vertical, the
global cell and gene therapy manufacturing market is slated to witness an
atrocious growth going forward”, says an analyst from Future Market Insights.
Key Companies Profiled:
Thermo Fisher Scientific, Merck KGaA, Lonza, Catalent Inc.,
Takara Bio Inc., F. Hoffmann-La Roche Ltd, Wuxi Advanced Therapies, Samsung
Biologics, Boehringer Ingelheim, Novartis AG, Hitachi Chemical Co., Ltd.,
Cellular Therapeutics, Miltenyi Biotec, Bluebird Bio Inc.
Get
More Insights@ https://www.futuremarketinsights.com/reports/cell-and-gene-therapy-manufacturing-market
Market
Segments Covered in Cell and Gene Therapy Manufacturing Market Analysis
By
Therapy Type:
- Cell
Therapy Manufacturing
- Stem
Cell Therapy
- Non-Stem
Cell Therapy
- Gene
Therapy Manufacturing
By
Scale:
- Pre-commercial/
R&D Manufacturing
- Commercial
Scale Manufacturing
By
Mode:
- Contract
Manufacturing
- In-house
Manufacturing
By
Workflow:
- Cell
Processing
- Cell
Banking
- Process
Development
- Fill
& Finish Operations
- Analytical
And Quality Testing
- Raw
Material Testing
- Vector
Production
- Other
Workflows
Comments
Post a Comment